A multicentre, retrospective, cohort study analysing Efficacy of cabozantinib in MiT family translocation renal cell carcinomas
Latest Information Update: 22 Mar 2021
Price :
$35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Mar 2021 New trial record
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium